Latest peptide research, regulatory updates, and industry news. Your daily source for peptide science developments.
Wegovy HD 7.2 mg CHMP positive opinion, Foundayo Week 6 IQVIA ~17K vs Wegovy pill ~142K, ASCO May 26 embargoed press briefing, Memorial Day dual-meeting week.
Read digest →Sapience lucicebtide GBM ASCO, Leerink/RBC TRIUMPH-1 weekend commentary, Corbus CRB-701 Nectin-4, Anglia Ruskin 90K-patient GLP-1 CV meta-analysis, EASL preview.
Read digest →Wegovy pill EU CHMP positive opinion, retatrutide TRIUMPH-1 analyst dysesthesia signal, Bicycle Duravelo-2 Phase 2 65% ORR, Hims $350M convertible, BriaCell 16.6mo OS.
Read digest →Retatrutide TRIUMPH-1 Phase 3 hits 28.3% weight loss + 30.3% extension, ASCO 2026 abstracts release, Regeneron-Parabilis $2.325B Helicon deal, AMAZE-12 amycretin Phase 3.
Read digest →Novo Nordisk pre-EASL ESSENCE liver safety, Parabilis IPO for zolucatetide, 20n Bio cyclic peptide AI, 5W AI citation index, CAMPER anti-MRSA peptide.
Read digest →Ozari Health telehealth $86/mo, Avacta AVA6103 FOCUS-01 Phase 1, MetaVia DA-1726 ADA, PCAC Feb 2027, TerminaTOR mTORC1, chiral peptide-drug conjugates.
Read digest →Novo international Wegovy pill expansion as US scripts cross 2M, BriaCell Bria-OVA+ ovarian pipeline, Tsinghua NK2R AI competition, Aivocode CAQK, Fibulin-4.
Read digest →Wegovy pill scripts decline for first time, Foundayo Week 5 +40%, Lilly analyst targets, Nature Biotech TCR PRP paper, retatrutide TRIUMPH timing, ASCO 2026.
Read digest →Foundayo Week 5 IQVIA 10,248 (+40% w/w), Hims 125K Wegovy shipments, daraxonrasib NEJM PDAC, FDA AI inspection pilot, peptide cancer vaccine reviews.
Read digest →ECO 2026 closes: SURMOUNT-MAINTAIN Lancet 7x maintenance odds, medRxiv $28-140/year generic semaglutide cost, Crinetics CAREFNDR + Cushing's, HIMS post-Q1.
Read digest →ECO Day 3: EASO 2026 framework first-line tirzepatide/semaglutide, CagriSema CV risk, RESETTLE young adults, Mazdutide GLORY-2 18.55%, JPM/Canaccord Hims.
Read digest →ECO Day 2: Lilly MAINTAIN dual publication, Viking VK2735 oral 12.2%, Wegovy Pill OASIS 4 21.6% early responders, ORION Wegovy vs Foundayo ITC, PepGen DM1.
Read digest →Bariatric surgery procedures dropped below 200,000 in 2024 — the first time since 2020 — as GLP-1 prescriptions grew from 4,600 in 2018 to 1.4 million in 2025. Wegovy 14.9%, Zepbound 22.5%, Wegovy HD 20.7%, and retatrutide 28.3% now overlap substantially with sleeve gastrectomy (25-30%) and Roux-en-Y gastric bypass (30-35%). Here's what the comparison actually shows, where surgery still wins, where pharmacology now wins, and how to think about your own decision.
20.9% of TRIUMPH-4 participants on retatrutide 12 mg and 12.5% in TRIUMPH-1 reported dysesthesia — abnormal skin sensations that didn't appear in the tirzepatide or semaglutide development programs. The signal traces to retatrutide's third receptor arm: glucagon. Here's what the trial data showed, the most-likely mechanism, why the effect is dose-dependent, and how prescribers should think about it ahead of the 2027 approval window.
Eli Lilly released TRIUMPH-1 Phase 3 topline May 21: retatrutide produced 28.3% mean weight loss at 12 mg over 80 weeks, 30.3% in the 104-week BMI ≥35 extension, and 45.3% of participants reached ≥30% weight loss — bariatric-surgery territory. The NDA filing is now Q4 2026 / Q1 2027, with TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + cardiovascular disease) still pending later this year. Here's what the readout means for patients deciding between starting Wegovy or Zepbound now and waiting for retatrutide.